Can you stomach a growth portfolio?

Small-cap growth stocks are far more volatile than anything that's in the S&P 500 index, but it's worth your while to strengthen your stomach. Why? Well, don't you want to be like the man who bought Motorola when it was a tiny radio manufacturer back in 1955 and never sold? He multiplied his money many, many times over, and that one experience -- and others like it -- helped him become one of the best investors of all time.

But you didn't need to be investing in 1955 to profit from Motorola's amazing growth. If you had bought the stock as late as 1980 and held, through even the company's turbulent recent years, the investment would still have brought you a return of 1,800%, turning $10,000 into $190,000.

Those types of returns are precisely why you should not only stomach growth stocks but make them a part of your portfolio today.

The growth king
The Motorola man I mentioned above is the famous Philip Fisher, and in 1958 he wrote Common Stocks and Uncommon Profits -- a timeless book for all investors. His greatest contribution to growth investing may be his 15 Points. Though they won't shield you from short-term volatility, these points will help you achieve incredible long-term returns.

Here's the short-short version ...

  1. Great growth stocks must take advantage of a substantial market opportunity to profit. That means they will be both "fortunate and able." Of course, being fortunate and able requires many things, including an excellent industry position, competitive advantages, prudent uses of discretionary dollars, efficient models, and superior sales forces.
  2. Great growth stocks must have a balanced and transparent management team. A potential investor must be able to look at a company's leadership and believe that it has integrity, an ability to handle distress, and an insightful vision for the future.
  3. Great growth stocks must have outstanding accounting and disclosure policies. Anything less than excellence is unacceptable.

How do these qualities translate to significant shareholder return? Examine Fisher's investment in steel maker Nucor in the mid-1970s. This was a growth mover at the time that went from a relative pip-squeak to the second-largest American steel manufacturer by the time Fisher sold it.

Nucor embodied some of the very basic principles that Fisher espoused. For example, when many steel makers were concentrating on volume and turnout, Nucor focused on implementing new technologies into its production methods, making each of its plants smaller, more efficient, and most importantly, more profitable. And today the company still looks like a little brother compared with big players such as Arcelor Mittal, Posco, and even relatively smaller firms like Gerdau (NYSE:GGB).

But again, you didn't need to be Fisher to take advantage. Even if you had bought Nucor stock in 1990, long after the company's initial move, you would have a fat 1,895% return on your hands. That's an 18.1% annual return compared with the market's 8.2%.

The next wave
I'm an analyst on the Motley Fool's Rule Breakers growth service, and I am constantly on the prowl for the best growth stocks out there. So with an eye on Fisher's most important lessons, here are three growth stocks that I believe have tremendous potential:

Company

Market Cap (millions)

Forward P/E

Long-Term Growth Estimate

Palomar Medical Technologies (NASDAQ:PMTI)

$336

14

18%

Double-Take Software (NASDAQ:DBTK)

$546

35

25%

Callaway Golf (NYSE:ELY)

$1,198

16

12%

Let's start with the name that's probably most familiar to you: Callaway. This stalwart of the golf world does battle with giants such as Nike and Taylor Made and yet has steadily improved returns on capital for the past several years. Margins are improving, and I'm looking to one catalyst to help take this stock into orbit: international growth.

As the world begins to bear the riches of development, so too will its golf courses and bags. Think Asia and Latin America.

Palomar Technologies is in a rut right now. The company develops non-surgical cosmetic devices, and it's no surprise that in a slowing U.S. economy, among the first expenses sacrificed are non-necessary medical procedures. The stock shows it too: Since February, it has shed more than 60%. Besides the fact that the company is dirt cheap, Palomar has a proven license portfolio that has been battle-tested in court. Consumer powerhouse Procter & Gamble (NYSE:PG) has signed up with Palomar as a partner to distribute its at-home products. After this larger economic malaise is over, you'll find that this is a well-priced stock that dominates a long-term growth industry.  

Double-Take Software is making a name for itself in the field of data protection. The company provides a low-cost software option for corporations looking to create redundancy systems and backup solutions without adding expensive infrastructure. In addition to being an acquisition candidate for any number of companies, including Microsoft (NASDAQ:MSFT), Double-Take is rapidly gaining acclaim in this vital field.

More where those came from
These are three of my favorite growth picks, and I look forward to seeing them flourish. Fisher's principles, which are elemental in my own approach, are also a big part of how we research at Rule Breakers -- where growth is king.

If these principles agree with your style, then I advise you to try the service free for 30 days. We're thumping the market average right now by nearly 25 percentage points. You can see all of our research and recommendations immediately upon joining, and there is no obligation to subscribe.

This article was first published July 30, 2007. It has been updated. 

Rule Breakers analyst Nick Kapur owns no shares of any company mentioned. Posco is an Income Investor recommendation. Microsoft is an Inside Value selection. The Motley Fool has a disclosure policy.